Bayer Growth Ventures backs Medopad $25m series-B

NWS Holdings and Healthbox also participated in the round, according to Venturebase.

The fresh capital will be used to finance new clinical studies and to continue the development of the company's AI-based health platform.

Previous funding
Medopad raised $28m in its series-A round in January 2018, backed by investors including Hong Kong-based NWS Holdings.

Company
Medopad provides AI-based technology to detect chronic diseases, using digital biomarkers to collect data from patients. The technology remotely monitors patients and aims to detect diseases such as Alzheimer's at an early stage.

The group was founded in London in 2011 and employs 50 staff. The company acquired San Francisco-based peer Sherbit in September 2018 and has partnerships with healthcare providers in the UK and China.

People
Medopad – Dan Vahdat (founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Technology
• Venture